On February 25, 2026, the U.S. Food and Drug Administration (FDA) issued full approval for Pfizer’s Braftovi (encorafenib) in combination with Erbitux (cetuximab) and chemotherapy for the first-line treatment of adults with metastatic colorectal cancer harboring the BRAF V600E mutation. This regulatory milestone is supported by evidence from the Phase 3 Breakwater trial.
The study demonstrated significant improvements in both progression-free survival and overall survival among participants receiving the triple-combination regimen. Originally granted accelerated approval in late 2024 based on response rates, this full authorization validates the therapy’s potential to redefine the standard of care for an aggressive and historically difficult-to-treat cancer subtype.
The safety profile observed in the trial was consistent with previous findings, with common adverse events including nausea, fatigue, and diarrhea. Permanent discontinuation rates due to side effects remained relatively low, ranging from 9% to 14% across different chemotherapy cohorts. European regulators are currently reviewing the combination for potential approval, following recent authorizations in several other international markets.